MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-14-2026
AstraZeneca PLC Total Shareholders Equity 2011-2026 | AZN
Annual Total Shareholders Equity AstraZeneca PLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.7 B | 40.9 B | 39.2 B | 37.1 B | - | 15.6 B | 14.6 B | 14 B | 16.6 B | 16.7 B | 18.5 B | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 48.7 B | 14 B | 26.2 B |
Quarterly Total Shareholders Equity AstraZeneca PLC
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.7 B | 44.8 B | 40.9 B | 39.6 B | 39.2 B | 37.4 B | - | - | - | - | 39.3 B | - | 15.7 B | - | 15.6 B | - | 13.7 B | - | 14.6 B | - | 15.1 B | - | 14 B | - | 14.3 B | - | 16.6 B | - | 15.4 B | - | 16.7 B | - | - | - | 18.5 B | - | - | - | 19.6 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 48.7 B | 13.7 B | 25.2 B |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
24.3 M | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 16.93 | -2.11 % | $ 791 M |  USA |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B | France |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 7.44 | -4.98 % | $ 204 M |  Israel |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-14.6 M | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
3.97 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AbCellera Biologics
ABCL
|
967 M | $ 4.03 | -8.33 % | $ 1.2 B | Canada |
 |
Compugen Ltd.
CGEN
|
103 M | $ 2.86 | -5.78 % | $ 267 M | Israel |
 |
Autolus Therapeutics plc
AUTL
|
178 M | $ 1.57 | -1.26 % | $ 418 M | Britain |
 |
BioNTech SE
BNTX
|
19.2 B | $ 89.03 | -3.22 % | $ 21.5 B | Germany |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.58 | -3.07 % | $ 185 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 3.36 | -3.72 % | $ 5.53 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.73 | -0.98 % | $ 33.4 M | Israel |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Eton Pharmaceuticals
ETON
|
26.2 M | $ 29.76 | -0.67 % | $ 801 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Exelixis
EXEL
|
2.16 B | $ 49.98 | -2.19 % | $ 13.6 B | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 21.8 | 1.07 % | $ 2.77 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Fortress Biotech
FBIO
|
49.9 M | $ 2.39 | 3.83 % | $ 66.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
|
Forte Biosciences
FBRX
|
61 M | $ 22.73 | -5.13 % | $ 294 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
35.5 M | $ 9.58 | 3.7 % | $ 274 M | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |